var data={"title":"Flucytosine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Flucytosine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6204?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=flucytosine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Flucytosine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=flucytosine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Flucytosine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708774\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Monitoring:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Use with extreme caution in patients with renal impairment. Close monitoring of hematologic, renal, and hepatic status of all patients is essential.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171786\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Ancobon</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171821\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antifungal Agent, Oral</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171790\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Usual dosage ranges:</b> Oral: 50 to 150 mg/kg/day in divided doses every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidiasis (off-label dose) (IDSA [Pappas 2016]):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Central nervous system (eg, meningitis):</i> 25 mg/kg/dose 4 times daily (with amphotericin B [liposomal]) until step-down therapy is clinically appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Cystitis, symptomatic:</i> Fluconazole-resistant <i>C. glabrata</i>: 25 mg/kg/dose 4 times daily for 7 to 10 days as monotherapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Endocarditis (native or prosthetic valve) or infected implantable cardiac devices (eg, pacemaker, ICD, VAD):</i> 25 mg/kg/dose 4 times daily (with an amphotericin B lipid formulation); for native or prosthetic valve endocarditis, therapy should continue for at least 6 weeks after valve replacement surgery (longer durations in patients with abscesses or other complications); for patients with implantable cardiac devices, therapy should continue for 4 to 6 weeks after surgery (4 weeks for infections limited to generator pockets and at least 6 weeks for infections involving the wires). <b>Note:</b> May transition to fluconazole if patient clinically stable with fluconazole-susceptible isolates in whom <i>Candida</i> has cleared from the bloodstream.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Endophthalmitis (with or without vitritis):</i> Fluconazole- or voriconazole-resistant isolates: 25 mg/kg/dose 4 times daily (with amphotericin B [liposomal]) for at least 4 to 6 weeks until examination indicates resolution; for patients with vitritis or with macular involvement (with or without vitritis), an intravitreal injection with voriconazole or amphotericin B deoxycholate is also recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Pyelonephritis, symptomatic:</i> Fluconazole-resistant <i>C. glabrata</i>: 25 mg/kg/dose 4 times daily in combination with amphotericin B deoxycholate for 1 to 7 days or as monotherapy for 14 days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cryptococcal meningitis, treatment:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Non-HIV-infected, non-transplant:</i> Induction: 25 mg/kg/dose (with amphotericin B) every 6 hours for at least 4 weeks; if clinical and microbiological improvement, may discontinue both amphotericin and flucytosine and follow with an extended course of fluconazole (IDSA [Perfect 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>HIV-infected or solid organ transplant recipients: </i>Induction: 25 mg/kg/dose (with amphotericin B) every 6 hours for at least 2 weeks; if clinical and microbiological improvement, may discontinue both amphotericin and flucytosine and follow with an extended course of fluconazole (HHS [OI adult 2017]; IDSA [Perfect 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Cerebral cryptococcomas: </i>Induction: 25 mg/kg/dose (with amphotericin B and corticosteroids) every 6 hours for at least 6 weeks, followed with an extended course of fluconazole (IDSA [Perfect 2010])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171809\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=flucytosine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Flucytosine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>General dosing, susceptible infections: </b>Infants, Children, and Adolescents (off-label population): Oral: 50 to 150 mg/kg/<b>day</b> in divided doses every 6 hours (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Aspergillosis, endocarditis (off-label use): </b>Limited data available: Children and Adolescents: Oral: 37.5 mg/kg/dose every 6 hours in combination with amphotericin B (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidiasis, endocarditis (off-label</b>\n      <b>):</b> Children and Adolescents: Oral: 37.5 mg/kg/dose every 6 hours in combination with amphotericin B (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cryptococcal meningitis, treatment: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Non-HIV-infected:</i> Children (off-label population): Oral: Induction: 25 mg/kg/dose (with amphotericin B) every 6 hours for at least 4 weeks; if clinical improvement, may discontinue both amphotericin and flucytosine and follow with an extended course of fluconazole (Perfect 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>HIV-infected:</i> Adolescents (off-label population): Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171791\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171792\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Adults: The manufacturer recommends dose reduction for elevated BUN or serum creatinine (or other signs of renal impairment); however, no specific dosage adjustments are provided. The following adjustments have been recommended (based on a usual dose of 25 mg/kg/dose every 6 hours):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;40 mL/minute: No dosage adjustment necessary (HHS [OI adult 2017]; IDSA [Perfect 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 20 to 40 mL/minute: 25 mg/kg/dose every 12 hours (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 10 to 20 mL/minute: 25 mg/kg/dose every 24 hours (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;10 mL/minute: 25 mg/kg/dose every 48 hours (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ESRD on intermittent hemodialysis (IHD): 25 to 50 mg/kg/dose every 48 to 72 hours; administer dose after hemodialysis (Drew 1999; HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants, Children, and Adolescents: The following adjustments have been recommended:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Aronoff 2007: Infants, Children, and non-HIV-exposed/positive Adolescents (based on a usual dose of 100 to 150 mg/kg/<b>day</b> divided every 6 hours):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR 30 to 50 mL/minute/1.73 m<sup>2</sup>: 25 to 37.5 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: 25 to 37.5 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: 25 to 37.5 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis: 25 to 37.5 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis: 25 to 37.5 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy: 25 to 37.5 mg/kg/dose every 8 hours (monitor serum concentrations)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HHS [OI pediatric] 2016: HIV-exposed/-positive: Children: Severe renal impairment: Avoid use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HHS [OI adult] 2017: HIV-exposed/-positive: Adolescents (based on a usual dose of 25 mg/kg/dose every 6 hours):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt;40 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 20 to 40 mL/minute: 25 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 10 to 20 mL/minute: 25 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;10 mL/minute: 25 mg/kg/dose every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ESRD on hemodialysis: 25 to 50 mg/kg/dose every 48 to 72 hours; administer dose after hemodialysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15881448\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171760\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ancobon: 250 mg, 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg, 500 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171744\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171765\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer around-the-clock to promote less variation in peak and trough serum levels. To reduce or avoid nausea and vomiting, administer a few capsules at a time over 15 minutes until full dose is taken.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171764\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Candida/Cryptococcus infections: </b>Adjunctive treatment of systemic fungal infections (eg, septicemia, endocarditis, UTI, meningitis, or pulmonary) caused by susceptible strains of <i>Candida</i> or <i>Cryptococcus</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50769419\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Aspergillosis, endocarditis treatment (pediatric)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171828\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Flucytosine may be confused with fludarabine, fluorouracil </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ancobon may be confused with Oncovin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171751\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cardiotoxicity, chest pain, ventricular dysfunction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Ataxia, confusion, fatigue, hallucination, headache, paresthesia, parkinsonian-like syndrome, peripheral neuropathy, psychosis, sedation, seizure, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus, skin photosensitivity, skin rash, toxic epidermal necrolysis, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hypoglycemia, hypokalemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, anorexia, diarrhea, duodenal ulcer, enterocolitis, gastrointestinal hemorrhage, nausea, ulcerative colitis, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Azotemia, crystalluria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Agranulocytosis, anemia, aplastic anemia, bone marrow aplasia, eosinophilia, leukopenia, pancytopenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatic injury (acute), hepatic insufficiency, hepatic necrosis, increased liver enzymes, increased serum bilirubin, jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Hearing loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased blood urea nitrogen, increased serum creatinine, renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dyspnea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171769\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to flucytosine or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171748\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hematologic disease: Use with caution in patients with bone marrow depression, hematologic disease or who have been treated with radiation or drugs that suppress the bone marrow; bone marrow toxicity may be irreversible. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; hepatotoxicity may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: <b>[US Boxed Warning]: Use with extreme caution in patients with renal dysfunction;</b> dosage adjustment required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Monitoring: <b>[US Boxed Warning]: Closely monitor hematologic, renal, and hepatic status.</b> Hepatotoxicity and bone marrow toxicity appear to be dose related; monitor levels closely and adjust dose accordingly. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Monotherapy: Avoid use as monotherapy; resistance rapidly develops.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299342\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171753\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8451&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: May enhance the adverse/toxic effect of Flucytosine. This may be related to the adverse effects of amphotericin B on renal function.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cytarabine (Conventional): May diminish the therapeutic effect of Flucytosine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gimeracil: May increase serum concentrations of the active metabolite(s) of Flucytosine. Specifically, gimeracil may increase concentrations of fluorouracil.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saccharomyces boulardii: Antifungal Agents (Systemic, Oral) may diminish the therapeutic effect of Saccharomyces boulardii. <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171782\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food decreases the rate, but not the extent of absorption.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171772\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies. Flucytosine is metabolized to fluorouracil which may cause adverse events if administered during pregnancy; refer to the Fluorouracil (Systemic) monograph for additional information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16355155\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if flucytosine is present in breast milk. Due to the potential for serious adverse reactions in the breastfeeding infant, a decision should be made whether to discontinue breastfeeding or the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171758\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pretreatment: Electrolytes (especially potassium), CBC with differential, BUN, renal function, blood culture</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">During treatment: CBC with differential and LFTs (eg, alkaline phosphatase, AST/ALT) frequently; serum flucytosine concentrations (2 hours after administration of a dose) after the initial 3 to 5 days of treatment (HHS [OI adult 2017]; IDSA [Perfect 2010]) and as clinically indicated; renal function</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171761\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Therapeutic: 30 to 80 mcg/mL (treatment of cryptococcal infections [HHS (OI adult 2017)]; IDSA [(Perfect 2010)]); serum concentrations should not exceed 100 mcg/mL to avoid bone marrow toxicity and hepatotoxicity. Serum concentrations should be measured after the initial 3 to 5 days of treatment, 2 hours after administration of a dose (HHS [OI adult 2017]; IDSA [Perfect 2010]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171747\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Penetrates fungal cells and is converted to fluorouracil which competes with uracil interfering with fungal RNA and protein synthesis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171768\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Rapid; serum concentrations are highly variable in neonates; monitor closely (Pasqualotto 2007); serum concentrations tended to be higher in children &lt;12 years of age; monitor closely (Soltani 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Into CSF, aqueous humor, joints, peritoneal fluid; V<sub>d</sub>: 0.6 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 3% to 4%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Minimally hepatic; deaminated both in yeasts and possibly via gut bacteria to 5-fluorouracil</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: 78% to 89%; decreased in neonates</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates: 4 to 34 hours (Baley 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants: 7.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 2 to 5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Anuria: 85 hours (range: 30 to 250)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">End-stage renal disease (ESRD): 75 to 200 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: ~1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates: 2.5 &plusmn; 1.3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: ~1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (&gt;90% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171771\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Ancobon Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $9,221.24</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $17,843.26</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Flucytosine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $8,206.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $15,880.50</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038617\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alcobon (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, NZ, OM, SA, SY, YE);</li>\n      <li>Ancobon (HK);</li>\n      <li>Ancotil (AE, AT, AU, BG, BH, BR, CH, CY, CZ, DE, DK, EG, FR, GB, GR, HR, IE, IL, IQ, IR, IT, JO, KW, LB, LY, NL, NO, OM, PL, QA, SA, SE, SG, SY, YE);</li>\n      <li>Ancotyl (RU);</li>\n      <li>Cocol (JP);</li>\n      <li>Flusine (TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ancobon (flucytosine) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed, Philadelphia, PA: American College of Physicians, 2007, 70, 158.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ASHP. Standardize 4 Safety Initiative Compounded Oral Liquid Version 1.01. July 2017. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/s4s-ashp-oral-compound-liquids.ashx?la=en&amp;hash=4C2E4F370B665C028981B61F6210335AD5D0D1D6.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baley JE, Meyers C, Kliegman RM, et al, &ldquo;Pharmacokinetics, Outcome of Treatment, and Toxic Effects of Amphotericin B and 5-Fluorocytosine in Neonates,&rdquo; <i>J Pediatr</i>, 1990, 116(5):791-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flucytosine-drug-information/abstract-text/2329429/pubmed\" target=\"_blank\" id=\"2329429\">2329429</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baltimore RS, Gewitz M, Baddour LM, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515. doi: 10.1161/CIR.0000000000000298<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flucytosine-drug-information/abstract-text/26373317/pubmed\" target=\"_blank\" id=\"26373317\">26373317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Drew RH, Perfect JR. Flucytosine. In: Yu VL, Merigan TC, Barriere SL, eds. Antimicrobial therapy and vaccines. Baltimore, MD: Williams and Wilkins; 1999:1170-1184.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gould FK, Denning DW, Elliott TS, et al, &ldquo;Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults: A Report of the Working Party of the British Society for Antimicrobial Chemotherapy,&rdquo; <i>J Antimicrob Chemother</i>, 2012, 67(2):269-89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flucytosine-drug-information/abstract-text/22086858/pubmed\" target=\"_blank\" id=\"22086858\">22086858</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed July 11, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lau AH and Kronfol NO, &ldquo;Elimination of Flucytosine by Continuous Hemofiltration,&rdquo; <i>Am J Nephrol</i>, 1995, 15(4):327-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flucytosine-drug-information/abstract-text/7573192/pubmed\" target=\"_blank\" id=\"7573192\">7573192</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lyman CA and Walsh TJ, &ldquo;Systemically Administered Antifungal Agents. A Review of Their Clinical Pharmacology and Therapeutic Applications,&rdquo; <i>Drugs</i>, 1992, 44(1):9-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flucytosine-drug-information/abstract-text/1379913/pubmed\" target=\"_blank\" id=\"1379913\">1379913</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2016;62(4):e1-e50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flucytosine-drug-information/abstract-text/26679628/pubmed\" target=\"_blank\" id=\"26679628\">26679628</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pasqualotto AC, Howard SJ, Moore CB, et al. Flucytosine Therapeutic Monitoring: 15 Years Experience From the UK. <i>J Antimicrob Chemother</i>. 2007;59(4):791-793.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flucytosine-drug-information/abstract-text/17339279/pubmed\" target=\"_blank\" id=\"17339279\">17339279</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patel R, &ldquo;Antifungal Agents. Part I. Amphotericin B Preparations and Flucytosine,&rdquo; <i>Mayo Clin Proc</i>, 1998, 73(12):1205-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flucytosine-drug-information/abstract-text/9868423/pubmed\" target=\"_blank\" id=\"9868423\">9868423</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perfect JR, Dismukes WE, Dromer F, et al, &quot;Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2010, 50(3):291-322.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flucytosine-drug-information/abstract-text/20047480/pubmed\" target=\"_blank\" id=\"20047480\">20047480</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saag MS, Graybill RJ, Larsen RA, et al, &ldquo;Practice Guidelines for the Management of Cryptococcal Disease. Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2000, 30(4):710-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flucytosine-drug-information/abstract-text/10770733/pubmed\" target=\"_blank\" id=\"10770733\">10770733</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Soltani M, Tobin CM, Bowker KE, et al, &quot;Evidence of Excessive Concentrations of 5-Flucytosine in Children Aged Below 12 Years: A 12-Year Review of Serum Concentrations From a UK Clinical Assay Reference Laboratory,&quot; <i>Int J Antimicrob Agents</i>, 2006, 28(6):574-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flucytosine-drug-information/abstract-text/17085019/pubmed\" target=\"_blank\" id=\"17085019\">17085019</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    VandenBussche HL, Johnson CE, Yun J, et al. Stability of flucytosine 50 mg/mL in extemporaneous oral liquid formulations. <i>Am J Health Syst Pharm</i>. 2002;93(19):1853-1855.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flucytosine-drug-information/abstract-text/12374070/pubmed\" target=\"_blank\" id=\"12374070\">12374070</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vermes A, Guchelaar H, and Dankert J, &ldquo;Flucytosine: A Review of its Pharmacology, Clinical Indications, Pharmacokinetics, Toxicity and Drug Interactions,&rdquo; <i>J Antimicrob Chemother</i>, 2000, 46(2):171-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flucytosine-drug-information/abstract-text/10933638/pubmed\" target=\"_blank\" id=\"10933638\">10933638</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8451 Version 130.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708774\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F171786\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F171821\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F171790\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F171809\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F171791\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F171792\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15881448\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F171760\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F171744\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F171765\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F171764\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F50769419\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F171828\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F171751\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F171769\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F171748\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299342\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F171753\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F171782\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F171772\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F16355155\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F171758\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F171761\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F171747\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F171768\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F171771\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038617\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8451|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=flucytosine-patient-drug-information\" class=\"drug drug_patient\">Flucytosine: Patient drug information</a></li><li><a href=\"topic.htm?path=flucytosine-pediatric-drug-information\" class=\"drug drug_pediatric\">Flucytosine: Pediatric drug information</a></li></ul></div></div>","javascript":null}